Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: A pharmacokinetic study in healthy volunteers

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 489-496

  Hammarberg, Anders ^a   Beck, Olof ^b   Eksborg, Staffan ^b   Jayaram Lindström, Nitya ^a   Lindefeldt, Annika ^b   Andersson, Maria ^b   Brundin, Lou ^c   Reid, Malcolm S ^c   Franck, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acamprosate; alcohol; LC MS; pharmacokinetics; treatment

Indexed keywords

ACAMPROSATE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE DEFICIENT TRANSFERRIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CREATININE; GAMMA GLUTAMYLTRANSFERASE; DRUGS USED IN THE TREATMENT OF ADDICTION; TAURINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VALIDATION STUDY; VOMITING; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CALIBRATION; CEREBROSPINAL FLUID; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; REPRODUCIBILITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALCOHOL DETERRENTS; AREA UNDER CURVE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TAURINE; YOUNG ADULT;

EID: 77955174662     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181e18638     Document Type: Article

References (34)

1. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22:573-579.
2. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
3. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996; 347:1438-1442.
4. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-99.
5. Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000;35:202-209.
6. Hammarberg A, Jayaram-Lindström, Beck O, et al. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacol (Berl). 2009; 205:53-62.
7. Rammes G, Mahal B, Putzke J, et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology. 2001;40:749-760.
8. Zeise ML, Kasparov S, Capogna M, et al. Acamprosate (calciumace- tylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol. 1993;231:47-52.
9. Mason BJ, Crean R. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev Neurother. 2007;7: 1465-1477.
10. Saivin S, Hulot T, Chabac S, et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet. 1998;35:331-345.
11. Zornoza T, Canot MJ, Polache A, et al. Pharmacology of acamprosate: an overview. CNS Drug Rev. 2003;9:359-374.
12. Mason BJ, Goodman MA, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. 2002;27:596-606.
13. Johnson, BA, OMalley SS, Ciraulo DA, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol. 2003; 23:281-293.
14. Chabenat C, Ladure P, Blanc-Continsouza D, et al. Determination of calcium acetylhomotaurinate by liquid chromatography with fluorimetric and electrochemical detection. J Chromatogr. 1987;414:417-422.
15. Girault J, Gobin, J, Fourtillan JB. Determination of calcium acetylhomo-taurinate in human plasma and urine by combined gas chromatography-negative-ion chemical ionization mass spectrometry. J Chromatogr. 1990; 530:295-305.
16. Rhee YS, Park JH, Park S, et al. Analysis of acamprosate in beagle dog plasma by LC-MS-MS. Arch Pharm Res. 2008;31:1035-1039.
17. Burattini C, McGeehan AJ, Griffin WC 3rd, et al. A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration. Addict Biol. 2008; 13:70-79.
18. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction. 1993;88:791-804.
19. Berman AH, Palmstierna T, Källmén H, et al. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res. 2004;11:22-31.
20. Sobell LC, Sobell MB. Timeline Follow Back. A technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen J, eds. Measuring Alcohol Consumption. Toronto: Humana Press; 1992:41-72.
21. Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974;2:123-148.
22. Wohl H. The cusum plot: its utility in the analysis of clinical data. N Engl J Med. 1977;296:1044-1045.
23. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.
24. Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-1462.
25. Ooteman W, Koeter MW, Verheul R, et al. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol. 2007;17:558-566.
26. Hammarberg, A, Wennberg P, Beck O, et al. A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate. Alcohol Alcohol. 2004;39:251-255.
27. Haug G. Pharmacokinetic study of 2 acamprosate tablets (23333 mg) in patients with different stages of impaired liver function compared to a control of healthy volunteers. Lyon, France: Lipha Pharmaceuticals, Inc; 1992:90235
28. Fourtillan JB.Pharmacokinetics of acetylhomotaurinate (AOTA) in young healthy volunteers subjects after single and multiple oral administrations of doses equal to 666 mg of calcium acetylhomotaurinate (AOTA-Ca). Lyon, France: Lipha Pharmaceuticals, Inc; 1990:AD 875 H
29. Campral, prescribing information. European summary of product characteristics. Lyon, France: Lipha Pharmaceuticals, Inc; 1995.
30. Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006;40: 383-393.
31. Durbin P, Belleville M. Rat pharmacokinetic profile of acamprosate in plasma, brain and CSF. Alcohol Alcohol. 1995;30:548.
32. Berton F, Francesconi WG, Madamba SG, et al. Acamprosate enhances N-methyl-D-aspartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res. 1998;22:183-291.
33. Cano-Cebrián MJ, Zornoza-Sabina T, Guerri C, et al. Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:119-225.
34. Kiefer F, Jahn H, Otte C, Nakovics H, et al. Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference. Neurosci Lett. 2006;404:103-106.